“…Over the last years, sST2 has been considered as a very promising biomarker to diagnose or monitor patients with One-vessel disease, n (%) 57 (21) Two-vessel disease, n (%) 37 (14) Three-vessel disease, n (%) 52 (19) Myocardial infarction, n (%) 28 (10) Atrial fibrillation, n (%) 26 (9) Stroke, n (%) 10 (4) Peripheral artery disease, n (%) 77 (28) COPD, n (%) 64 (23) Transfemoral access, n (%) 212 (77) heart failure and was investigated as a biomarker in many large clinical trials, mainly in heart failure patients, but also in patients with myocardial infarction [26,28,29]. Moreover, sST2 Figure 1 After 1 year, patients with a sST2 concentration above the optimal cut-off of 10 070Á27 pg/mL evidenced a significantly worse outcome (49Á2% vs. 23Á2%; OR 3Á21 95% CI (1Á70-6Á04); P < 0Á001).…”